"The subject expert committee (SEC), a body under the drug regulator, did not find any "scientific rationale" to conduct phase-3 trials and hence did not consider Dr Reddy's application seeking to carry out trials in India," sources say.from Industry-Economic Times
Read The Rest:economictimes...
